Core Insights - The company is advancing its novel Doxorubicin containing Microneedle Array (D-MNA) treatment for non-invasive basal cell carcinoma (BCC) and developing Teverelix, a next-generation GnRH Antagonist for Acute Urinary Retention (AURr) and high cardiovascular risk prostate cancer [1] Market Opportunity - D-MNA and Teverelix collectively represent approximately $8 billion in potential market opportunity [1] Company Activities - The company will participate in a live fireside chat on September 29, 2025, hosted by Kumaraguru (Kumar) Raja, Ph.D. [1]